Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment

Fig. 6

PTC-209 inhibits osteogenesis via upregulation of DKK1. a PTC-209 significantly inhibited osteoblast formation in a dose-dependent manner verified by reduced alkaline phosphatase activity and matrix mineralization at days 14 and 21 of differentiation, respectively. Images are representative for three independent experiments. b Treatment with PTC-209 increased DKK1 expression in developing osteoblasts at day 14 of osteogenesis. c The inhibitory effect of PTC-209 on osteoblast activity was partially overcome by concurrent anti-DKK1 antibody treatment. ***P < 0.001, **P < 0.01 and *P < 0.05 vs DMSO control; # P < 0.05

Back to article page